TAKIS SRL

Their core work

Takis is a Rome-based biotech SME specializing in cancer immunotherapy and advanced therapeutic development. Their core work centers on DNA electroporation (DNA-EP) vaccine platforms for personalized cancer treatment, while also contributing to targeted drug delivery and gene/cell therapy research for rare diseases. They bridge preclinical research and early-stage therapeutic development, operating at the intersection of immunology, oncology, and advanced therapy medicinal products (ATMPs).

What they specialise in

How they've shifted over time

Takis entered H2020 in 2019 with a focused bet on personalized cancer immunotherapy (TK-NEO, SME Phase 1), signaling early commercial ambitions around their DNA-EP vaccine platform. Their subsequent projects broadened into targeted drug conjugates (Magicbullet Reloaded) and gene/cell therapy for rare diseases (ARDAT), indicating a deliberate expansion from oncology-only toward the wider advanced therapies space. This trajectory suggests a company moving from a single product concept toward becoming a broader platform contributor in therapeutic biologics.

Takis is expanding from cancer vaccines into the broader advanced therapies ecosystem, positioning itself as a specialist contributor in gene therapy and targeted drug delivery — sectors with growing EU funding and regulatory attention.

How they like to work

Takis operates primarily as a participant in larger consortia (2 of 3 projects), joining research-intensive networks like Magicbullet Reloaded (MSCA training network) and ARDAT (major RIA). Their one coordination was a small SME Phase 1 feasibility study, typical for biotech SMEs validating a commercial concept. With 49 unique partners across just 3 projects, they are embedded in large collaborative networks rather than leading them — a common and effective pattern for specialist SMEs contributing deep domain expertise to multi-partner efforts.

Despite only 3 projects, Takis has collaborated with 49 unique partners across 15 countries, reflecting their participation in large pan-European consortia. Their network spans broadly across the EU with no single dominant geographic cluster beyond their Italian base.

What sets them apart

Takis combines hands-on biotech R&D capability with EU project experience in a niche that few SMEs occupy: the development of DNA-based immunotherapy platforms and advanced therapeutic products. For consortium builders, they offer a rare profile — a small, agile Italian biotech that can contribute both proprietary technology (DNA-EP vaccines) and practical experience across multiple therapeutic modalities including targeted drug conjugates and gene therapy. Their SME status also strengthens proposal scoring for calls requiring industrial and SME participation.

Highlights from their portfolio

• TK-NEO
  Their only coordinated project — an SME Phase 1 feasibility study for personalized cancer immunotherapy, revealing their core commercial ambition around DNA-EP vaccines.
• ARDAT
  A major RIA running until 2026 focused on accelerating advanced therapies (gene/cell therapy for rare diseases), representing their largest single funding (EUR 225K) and longest commitment.
• Magicbullet Reloaded
  An MSCA training network on targeted drug conjugates for tumor therapy, showing Takis contributes to research training alongside established academic partners.